Carrying out activities to improve the lives of people all over the world since its establishment, Roche announced new position changes for its global structure and goals. As part of the changes to be made in the spring of 2023, Christopher Franz has decided not to seek re-election as Chairman of the Board of Directors, while Roche Group CEO Severin Schwan will be nominated as the Chairman of the Board. Thomas Schinecker, CEO of Roche Diagnostics, will replace Schwan starting from March 15, 2023.
Empowering the future of the healthcare ecosystem for 125 years, Roche will make significant changes in its senior structure. With the changes to be made in the company’s Board of Directors and Executive Board in March 2023, the Roche Group CEO will also change. Christoph Franz, who has been on Roche’s Board of Directors since 2011 and has served as the Chairman of the Board since 2014, announced that he has decided not to seek re-election as Chairman of the Board of Directors, while Severin Schwan, Roche Group CEO will be proposed to replace Franz. Thomas Schinecker, CEO of Roche Diagnostics, will replace Schwan with effect from March 15, 2023.
Talking about the new appointments Christoph Franz said “After serving twelve years on the Board of Directors, nine of which as Chairman, I have decided not to seek re-election to the Board next year. We have achieved many important milestones and with the conclusion of Roche’s 125th anniversary, it is now the right time for a change in leadership. I am proud of the significant contributions Roche has made in fighting the pandemic during the last two and a half years. With the strong pipelines of innovative products in both our Pharma and Diagnostic businesses, we are set for continued growth in the future.”
Severin Schwan, who has been a member of the Corporate Executive Committee since 2006, has been the Roche Group CEO since 2008 and on the Board of Directors since 2013, said ”I have very much appreciated the close and trusting collaboration with Christoph and would like to thank him. I am honoured to stand for the position of Chairman of the Roche Board of Directors and will continue to dedicate all my efforts to the future of this company.” He added “I am very pleased that the Board has appointed Thomas as the new Roche CEO. He is a highly qualified successor who has been working for Roche in leadership positions around the globe for twenty years. Thomas successfully set up our Diagnostics Division for the future. Under his leadership our Diagnostics organisation also made considerable contributions in fighting the COVID-19 pandemic.”
Thomas Schinecker, who will start working as Roche Group CEO as of March 15, 2023, said, “I am deeply honoured by the Board’s decision and the trust placed in me. I am delighted to carry on working closely with Roche colleagues and the Corporate Executive Committee. Like we’ve done for the last 125 years, I am excited about the future innovations we will bring to patients around the globe.”
M-TR-00002603
